Effects of WB-EMS and Dietetic Treatment on Cancer Patients
- Conditions
- Muscle LossCancer CachexiaCancerWeight LossMuscle Weakness
- Interventions
- Other: Whole-Body Electromyostimulation (WB-EMS)
- Registration Number
- NCT02293239
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Brief Summary
This study evaluates the effects of a 12-week whole-body electromyostimulation (WB-EMS) training combined with individualized nutritional support on body composition, muscle strength and function and quality of life of patients with malignant disease undergoing curative or palliative anti-cancer treatment
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 278
- malignant disease (solid or hematological cancer): head and neck cancer, colorectal carcinoma, small intestinal cancer, gastric cancer, oesophageal cancer, pancreas carcinoma, liver cell carcinoma, cholangiocarcinoma,lung cancer, breast cancer, cervix cancer, ovarian cancer, prostate cancer, renal cell carcinoma, malignant melanoma, patients with leukaemia and malignant lymphomas or Graft-versus-Host-Disease after bone marrow transplantation
- ongoing or planned curative or palliative anti-cancer therapy
- simultaneous participation in other nutritional or exercise intervention trials
- acute cardiovascular events
- use of anabolic medications
- epilepsy
- severe neurological diseases
- skin lesions in the area of electrodes
- energy active metals in body
- pregnancy
- acute vein thrombosis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description WB-EMS group Whole-Body Electromyostimulation (WB-EMS) physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min) + individualized nutritional support (dietary advices: daily protein intake \> 1.0 g/kg bodyweight)
- Primary Outcome Measures
Name Time Method Skeletal muscle mass 12 weeks Skeletal muscle mass assessed by bioelectrical impedance analysis (in kg)
Physical function - Gait pattern 12 weeks Sensor-based gait analysis
- Secondary Outcome Measures
Name Time Method Patient-reported performance status 12 weeks ECOG performance status/Karnofsky index
Patient-reported Fatigue 12 weeks FACIT-Fatigue scale
Patient-reported Quality of Life (QoL) 12 weeks EORTC QLQ - C30 questionnaire
Physical function - Endurance 12 weeks Six-minute-walk test (walking distance in m)
Physical function - Isometric muscle strength 12 weeks Hand grip strength assessed by hand dynamometer (in kg)
Physical function - Lower limb strength 12 weeks 30 second sit-to-stand test (number of sit-to-stand cycles)
Inflammatory blood markers 12 weeks Blood collection and analysis e.g. of C-reactive protein (CRP), Albumin
Trial Locations
- Locations (1)
Medizinische Klinik 1, University of Erlangen-Nürnberg
🇩🇪Erlangen, Bavaria / Franconia, Germany